Amphastar Pharmaceuticals... (AMPH)
Amphastar Pharmaceuticals Statistics
Share Statistics
Amphastar Pharmaceuticals has 47.5M shares outstanding. The number of shares has increased by -2.56% in one year.
Shares Outstanding | 47.5M |
Shares Change (YoY) | -2.56% |
Shares Change (QoQ) | -0.9% |
Owned by Institutions (%) | 72.87% |
Shares Floating | 35.08M |
Failed to Deliver (FTD) Shares | 1.32K |
FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 2.97M, so 6.25% of the outstanding shares have been sold short.
Short Interest | 2.97M |
Short % of Shares Out | 6.25% |
Short % of Float | 12.29% |
Short Ratio (days to cover) | 3.78 |
Valuation Ratios
The PE ratio is 11.27 and the forward PE ratio is 6.63. Amphastar Pharmaceuticals's PEG ratio is 0.73.
PE Ratio | 11.27 |
Forward PE | 6.63 |
PS Ratio | 2.52 |
Forward PS | 1.3 |
PB Ratio | 2.46 |
P/FCF Ratio | 10.43 |
PEG Ratio | 0.73 |
Enterprise Valuation
Amphastar Pharmaceuticals has an Enterprise Value (EV) of 2.3B.
EV / Sales | 3.22 |
EV / EBITDA | 8.28 |
EV / EBIT | 10.77 |
EV / FCF | 13.33 |
Financial Position
The company has a current ratio of 3.07, with a Debt / Equity ratio of 0.89.
Current Ratio | 3.07 |
Quick Ratio | 2.19 |
Debt / Equity | 0.89 |
Debt / EBITDA | 2.35 |
Debt / FCF | 3.77 |
Interest Coverage | 6.77 |
Financial Efficiency
Return on Equity is 21.78% and Return on Invested Capital is 12.28%.
Return on Equity | 21.78% |
Return on Assets | 10.11% |
Return on Invested Capital | 12.28% |
Revenue Per Employee | $351.49K |
Profits Per Employee | $78.66K |
Employee Count | 2,028 |
Asset Turnover | 0.45 |
Inventory Turnover | 2.2 |
Taxes
Income Tax | 29.67M |
Effective Tax Rate | 15.64% |
Stock Price Statistics
The stock price has increased by -41.99% in the last 52 weeks. The beta is 0.79, so Amphastar Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.79 |
52-Week Price Change | -41.99% |
50-Day Moving Average | 27.06 |
200-Day Moving Average | 39.14 |
Relative Strength Index (RSI) | 42.38 |
Average Volume (20 Days) | 612.24K |
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 712.81M and earned 159.52M in profits. Earnings per share was 3.29.
Revenue | 712.81M |
Gross Profit | 373.86M |
Operating Income | 205.42M |
Net Income | 159.52M |
EBITDA | 277.31M |
EBIT | 220.11M |
Earnings Per Share (EPS) | 3.29 |
Balance Sheet
The company has 151.61M in cash and 650.55M in debt, giving a net cash position of -498.94M.
Cash & Cash Equivalents | 151.61M |
Total Debt | 650.55M |
Net Cash | -498.94M |
Retained Earnings | 568.79M |
Total Assets | 1.58B |
Working Capital | 360.31M |
Cash Flow
In the last 12 months, operating cash flow was 213.39M and capital expenditures -41.04M, giving a free cash flow of 172.34M.
Operating Cash Flow | 213.39M |
Capital Expenditures | -41.04M |
Free Cash Flow | 172.34M |
FCF Per Share | 3.56 |
Margins
Gross margin is 52.45%, with operating and profit margins of 28.82% and 22.38%.
Gross Margin | 52.45% |
Operating Margin | 28.82% |
Pretax Margin | 26.62% |
Profit Margin | 22.38% |
EBITDA Margin | 38.9% |
EBIT Margin | 28.82% |
FCF Margin | 24.18% |
Dividends & Yields
AMPH does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 8.87% |
FCF Yield | 9.58% |
Analyst Forecast
The average price target for AMPH is $43.5, which is 78.2% higher than the current price. The consensus rating is "Hold".
Price Target | $43.5 |
Price Target Difference | 78.2% |
Analyst Consensus | Hold |
Analyst Count | 3 |
Scores
Altman Z-Score | 2.5 |
Piotroski F-Score | 5 |